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We previously reported that tau protein kinase I (TPKI) induced normal tau protein into a state of paired helical filaments (PHF); this is further 
confirmed here by tmmunoblot analysis using several antibodies. We also present the amino acid sequence of TPKI, which is identical to glycogen 
synthase kinase 38 (GSK3B). Moreover, we found that TPKI acttvity was inseparable from GSK3 acttvity throughout the purification procedure. 
These results indicate that TPKI is identical to GSK3/?. 
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1. INTRODUCTION 
Paired helical filaments (PHF) are one of the hall- 
marks in the brain of Alzheimer’s disease patients. The 
major component of PHF is abnormally phosphory- 
lated tau. Identification of the kinase responsible for 
this abnormal phosphorylation is important for an un- 
derstanding of the pathological change. We were the 
first to find a protein kinase activity generating a PHF 
epitope on tau from microtubule proteins of bovine 
brain [l]. The epitope was detected with anti-ptau 1 [2]. 
The protein kinase was independent of well-known sec- 
ond messengers, but tubulin stimulated the phosphoryl- 
ation of tau by the kinase. The kinase activity was asso- 
ciated with tau, and the best substrates in brain extract 
were tau and MAP2. According to these properties re- 
lating to tau, this enzyme was named tau protein kinase 
(TPK) (EC 2.7.1.135) [3]. Further purification revealed 
that the TPK fraction contained two kinases, TPKI and 
TPKII, and that TPKI generated the PHF epitope [4]. 
Phosphorylation of tau by TPKI was accelerated by 
prior phosphorylation by TPKII, suggesting that 
TPKII indirectly regulates the epitope’s formation [5]. 
We determined the phosphorylation sites on tau by both 
kinases, and found that these sites are in good agree- 
ment with those of PHF-tau [6]. Our immunochemical 
analyses suggested that TPKII works in normal brain 
[5]. On the other hand, the PHF epitope recognized by 
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anti-ptau 1 and generated by TPKI was never detected 
in normal tau, suggesting that TPKI is a candidate for 
the kinase leading to the conversion of tau to a PHF-like 
state. To confirm this working hypothesis, we have to 
prove that TPKI also induces some other immunoreac- 
tivities characteristic of PHF. We present here a result 
strengthening this hypothesis. 
Other groups have reported that mitogen-activated 
protein (MAP) kinase [7,8], cdc2 kinase [8,9] and glyco- 
gen synthase kinase 3 (GSK3) [lO,ll] are also candi- 
dates for the kinase inducing tau into the PHF-like 
state. Particularly, GSK3 exhibits a similar hierarchal 
phosphorylation process to TPKI [12,13]. In order to 
answer the question of whether or not TPKI is identical 
to these kinases, determination of the sequence of TPKI 
is required. Here, we report that the TPKI sequence is 
identical to that of GSK3P, which is derived from one 
of two classes of rat brain cDNA for GSK3, but not 
MAP kinase or cdc2 kinase. Furthermore, TPKI activ- 
ity is inseparable from GSK3 activity throughout puri- 
fication procedues. We conclude that TPKI is identical 
to GSK3/?. 
2. MATERIALS AND METHODS 
2.1. Materials 
TPKI, TPKII and tau were purified by the method described previ- 
ously [4]. GSK3jI was purified by the method of Woodgett [14], fol- 
lowed by gel filtration with G3000 SW (Tosoh). Casein kinase II was 
purified according to the method described by Cohen et al. [15]. Xen- 
opus MAP kinase [16] was a kind gift from Dr. Nishida (University 
of Tokyo). The kmase has 95% sequence homology to mammalian 
MAP kmase, ERK2 [17]. Glycogen synthase was purchased from 
Sigma. 
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Peptides named GS-1 and K2 were synthesized by the solid phase 
method, usmg a Biosearch model 9500 peptide synthesizer. The se- 
quence of GS- 1 was described in [ 181. The sequence of K 1. K2 and K3 
corresponded to ammo acid numbers 226-240, 189-224 and 396439 
of the longest human tau [19]. respectively. 
Anti-tau was purchased from Sigma. Monoclonal antibody, tau-1 
was from Boehringer-Mannheim. Three monoclonal antibodies 
against neurofilament SM131, SMI33 and SM134 [20], were from 
Sternberger monoclonals Inc. A polyclonal antibody against PHF, 
anti-ptau 1 121, was a kind gift from Dr. Ihara (University of Tokyo). 
2.2. Phosphorylrtzorz ofpeptides 
For the preparation of a substrate for TPKI assay, K2 was fully 
phosphorylated by TPKII and unlabelled ATP m a reaction medium 
described previously [S]. Then the solution was heated at 95°C for 5 
mm to Inactivate TPKII. For TPKI assay. the phosphorylated K2 
(p-K2) (0.12 mglml) was phosphorylated by TPKI and [y-“P]ATP (0.4 
mM, 15 mBq/ml) The assay solution was soaked onto P81 paper. and 
the paper uas washed four times in 1% phosphoric acid and then once 
in acetone. and was dried. The remaining radioactivity was counted 
by hquid scintillation counter. For GSK3 assay. we used GS-1 
phosphorylated by casem kinase II as a substrate [18]. 
2.3. Seyueming 
TPKI was digested by endoproteinase Lys-C (Boehrmger- 
Mannheim) at a protem ratio of 2O:l. The peptides were separated by 
reverse-phase column (CS) chromatography. The amino acid se- 
quences were determined by a pulse-liquid-phase amino acid se- 
quencer (Apphed Biosystems 477A protein sequencer). 
Bovine cerebrum cDNA was synthesized from poly(A)’ RNA pre- 
pared from bovme cerebrum with a cDNA synthesis kit (Pharmacia) 
PCR amphfication of an oligonucleotide primer corresponding to 
peptide D was carried out by GeneAmp DNA amphfication reagent 
kit (Perkm-Elmer Cetus) usmg the bovine cerebrum cDNA as a tem- 
N 1 
plate, and cDNA of rat TPKI was cloned from a /2gtll cDNA library 
(Clontech) using the PCR product as a probe. DNA was sequenced 
by dideoxy-mediated sequencing [21]. 
3. RESULTS 
Previously, we reported that tau phosphorylated by 
TPKI had at least one PHF epitope [4]. It was reported 
that there are some other epitope changes characteristic 
of PHF. We investigated the other epitope changes ac- 
companying the phosphorylation (Fig. 1). We also ob- 
served epitope changes induced by TPKII (a cdc2-like 
kinase; see section 4) and MAP kinase, since cdc2 kinase 
and MAP kinase have previously been suggested as 
other candidates for PHF formation [7-91. Neurofil- 
ament antibodies SM133, SM134 and SM13 1 are known 
to discriminate between tau and PHF. After phospho- 
rylation of tau by TPKI. epitope SM133 disappeared, 
epitope SM134 increased. and epitope SM131 appeared. 
These changes are expected for conversion of tau into 
PHF [20]. We have already reported that TPKI 
phosphorylated Ser-199, Thr-23 1, Ser-396 and Ser-413 
[22] in the numbering of the longest human tau [19], 
whereas TPKII phosphorylated Ser-202. Thr-205. Ser- 
235 and Ser-404 [23]. Since the SM133 epitope was 
reported to contain Ser-235 [20] which was 
phosphorylated by TPKII, TPKII made this epitope 
disappear. Considering that the same effect was shown 
2M N 
8 
a-tau 
Tau PHF 
+ - tau-1 
I 
I 
1 s199 ; SEE 
1 T231 
2 S235 
+ - SMI 33 
+ SMI 31 
1 S396 
: zK!i 
+ a-ptaul 5422 
Fig. 1 Immunoblot analyses of tau. Normal bovine tau was phosphorylated by TPKI, TPKII or Xerzopus MAP kinase. These proteins were 
immunoblotted with anti-tau (a-tau) (1:500). tau-1 (1’10.000). SM133 (l.l.OOO), SMI34 (l:l,OOO). SM131 (l:l.OOO) and anti-ptau 1 (a-ptaul) (1:50) 
The right panel indicates the recognition sites of tau-I [24]. SM131, SMI33, SM134 [20] and anti-ptau I [2] R l-R4 are repeats m the tubulm-bindmg 
region [19]. Open arrows Indicate phosphorylation sites reported by Mandelkow et al. [7.20,35]. Closed arrows indicate phosphorylation sites 
reported by us [22]. Numbers 1 and 2 adjacent to these arrows indicate sites phosphorylated by TPKI and TPKII, respectively. Ammo acid 
numbering is that found in the longest human tau [19]. The left table Indicates known epitope differences between normal tau and PHF-tau. In 
this table. plus or mmus mdicates whether or not a reaction occurs with the antibodies. respectively 
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Fig. 2. Elution profile of TPKI and TPKII at S-Sepharose column 
chromatography (step 6 of our purification method [4]). (A) Activities 
of TPKI (0) and TPKII (0). TPKII activity was measured by phos- 
phorylatlon of K2. TPKI activity was detected by phosphorylation of 
K2 previously phosphorylated by TPKII. (B) Protein profile of the 
fractions on SDS-PAGE. TPKI (45 kDa) and two polypeptides (30 
kDa and 23 kDa) of TPKII are indicated. 
by TPKI which phosphorylated Thr-231 near Ser-235, 
Thr-231 may also be essential for the SM133 epitope. 
The SM131 epitope was reported to be generated after 
phosphorylation of Ser-396 and Ser-404 [20]. Since nor- 
mal tau was partially phosphorylated at Ser-404 [5], and 
TPKI phosphorylated Ser-396, it is reasonable to sug- 
gest that TPKI could generate the SM131 epitope on 
normal tau. SM134 was reported to recognize a confor- 
mational change of a repeating region. We show here 
that the change was induced by TPKI, although the 
epitope was already found weakly in normal tau. The 
tau-1 epitope disappeared on tau showing large mobil- 
ity shift on SDS-PAGE after the phosphorylation by 
TPKI, indicating that the epitope contains Ser-199 [24]. 
TPKII and Xenopus MAP kinase also caused some, but 
not all, of the changes. In particular, MAP kinase could 
not generate the immunoreactivity recognized by anti- 
ptau 1, which was used as an antibody to detect conver- 
sion of tau into the PHF-like state for purification of 
TPKI [4]. The result strenghthened our working hy- 
pothesis that TPKI converts tau into the PHF state. 
To characterize TPKI, we next developed a specific 
method of assaying for TPKI with a peptide substrate, 
based on the fact that phosphorylation of tau by TPKI 
was accelerated by its prior phosphorylation by TPKII 
[5]. Using three synthetic peptides each having a partial 
sequence of tau (Kl, K2 and K3 [23]) we found that 
phosphorylation of Thr-231 in Kl and Ser-199 in K2 
was enhanced by prior phosphorylation of Ser-235 and 
Ser-202, respectively. The enhancement was larger in 
the case of K2 than that in the case of Kl. Therefore, 
we used K2 as a specific substrate for TPKI assay. 
Using the K2 phosphorylated by TPKII (p-K2) as a 
substrate. the activity of TPKI was measured at step 6 
in our purification procedure [4], where TPKI was sep- 
arated from TPKII. The phosphopeptide p-K2 was 
phosphorylated preferentially compared to K2, whereas 
TPKII phosphorylated only K2 (Fig. 2) indicating that 
this is a very effective and specific assay for TPKI. 
To clarify the identity of TPKI, we next studied its 
amino acid sequence. Seven peptides (peptides A-G) 
were obtained from endopeptidase digests of TPKI, and 
subjected to peptide sequence analysis. About 90 amino 
acid residues in total were determined. A homology 
search of the amino acid sequences against the SWISS- 
PROT database showed that all of the sequence was 
present in GSK3p [14] (Fig. 3). PCR amplification of an 
oligonucleotide primer corresponding to peptide D was 
carried out using bovine cerebrum cDNA as a template, 
and synthetic sense- and antisense-guessmers corre- 
sponding to the N- and C-terminal of peptide D, respec- 
tively. A PCR product was obtained that contained the 
nucleotide sequence consisting of the middle portion of 
the peptide D. Using this PCR fragment as a hybridiza- 
tion probe, cDNA of TPKI was cloned from a rat brain 
cDNA library, and its sequence was determined. The 
sequence of TPKI is presented in Fig. 3. The amino acid 
sequence deduced from the nucleotide sequence is com- 
pletely identical to that of GSK3P. In the nucleotide 
sequence, however. there are some differences; C(-103) 
in the sequence of GSK3P is deleted in that of TPKI. 
(-31)CC is TT, (718)ATG is GTA, (1,114)CCC is CCT, 
(1,168)CCT is CCG, (1.356)AAAAAA is AGAGGA 
(numbering in parentheses indicates nucleotide number 
of GSK3P [14]). 
To confirm the identity, we purified GSK3P from 
bovine brain by Woodgett’s method [14]. Detecting 
TPKI activity by the method mentioned above and 
GSK activity phosphorylating glycogen synthase, we 
confirmed that TPKI activity was inseparable from 
GSK activity throughout all steps of the purification. 
Additionally, phosphorylation of tau by the purified 
GSK3 was also stimulated by tubulin. This result sup- 
ports the identity. 
Furthermore, we proved that TPKI possessed GSK3 
activity by using a specific phosphopeptide substrate for 
GSK3. Phosphorylation of glycogen synthase by GSK3 
occurs at an amino acid very near the site 
phosphorylated by casein kinase II. GSK3 recognizes 
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the casein kinase II-modified serine residue and can 
then phosphorylate the second serine residue. This 
process was studied in detail using a peptide substrate, 
GS-1, that comprised a glycogen synthase sequence 
containing these phosphorylation sites [18]. Therefore, 
we measured GSK3 activity using the most highly puri- 
fied TPKI using GS- 1 peptide phosphorylated by casein 
kinase II as a substrate [18]. The phospho-GS-1. but not 
GS-1, was phosphorylated by the kinase activity in the 
purified TPKI (Fig. 4), indicating that the kinase is 
GSK3, i.e. TPKI. 
4. DISCUSSION 
Previously, we reported that TPKI generated one 
PHF epitope detected by anti-ptau 1 and diminished 
tau-1 epitope, as observed in PHF [1,4,22]. Here we 
showed that TPKI also induces some other im- 
munoreactivities characteristic of PHF, supporting our 
previous hypothesis that TPKI is the most likely of the 
leading candidates for the role of the PHF-related ki- 
nase. 
We also showed here that TPKI is identical to 
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Fig. 3. Sequence of rat TPKI. A nucleotide sequence between two arrows is that of GSK3/I already reported [14]. Lines above the sequence show 
nucleotide dtfferences from those in GSK3B. O, indicates the deletion of a single nucleottde. Underlines Indicate seven pepttdes, A-G determined 
from the TPKI digest with endoproteinase Lys-C (see text). Broken underlines show amino acids not determined. 
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Fig. 4. TPKI activity (A) and GSK3 activity (B) of the mostly highly 
purified TPKI. The activities were measured with the following pep- 
tides as substrates; K2 (0) and K2 phosphorylated by TPKII (0) in 
A, and GS-1 (0) and GS-1 phosphorylated by casein kinase II (0) 
in B. 
GSK3/?. GSK3 was originally found to be a kinase 
phosphorylating glycogen synthase in muscle [ 151. 
cDNA cloning showed the existence of another class of 
rat brain cDNA for GSK3 [ 141. Thus the original GSK3 
was called GSK3a, and the protein kinase found later 
was named GSK3/?. Recently, both GSK3a and GSK3/? 
have independently been reported to be the candidates 
for the abnormal phosphorylation of tau inducing PHF 
formation [lO,ll]. We detected the same epitope 
changes as those reported by Mandelkow et al. [l 11, 
although there were discrepancies between their and our 
estimation of the phosphorylation sites. 
The identity is supported by other properties of 
TPKI. TPKI was purified from microtubules and in- 
duced a large mobility shift of tau on SDS-PAGE [1,4]. 
F,/GSK3 was reported to be associated with microtu- 
bule and to induce large mobility shift of tau [25]. Fur- 
thermore, phosphorylation of tau by TPKI was ac- 
celarated by prior phosphorylation of tau by TPKII [5], 
a property which was useful for developing a specific 
assay for TPKI, as mentioned above. Considering that 
the recognition motif for GSK3 contains phosphoserine 
[12,13], it is reasonable to suggest that TPKI exhibits a 
similar hierarchal phosphorylation process. 
GSK3 is known to be a multifunctional kinase. We 
found here that the phosphorylation of tau is also one 
of its functions. According to enzyme nomenclature, the 
kinase has been given various names based on the sub- 
strate; GSK3 [15], ATP-citrate lyase kinase [26], c-jun 
kinase [27], TPKI [4], and so on. Moreover, the kinase 
is also called factor A (FA), because the kinase is an 
activating factor of phosphoprotein phosphatase 1 
[28,29]. Properly, a multifunctional kinase should be 
given a name that represents its generalized function, 
and not a name dependent on the substrate in a single 
reaction. Further investigation will be necessary for 
providing an understanding of the features common 
among the various substrates. Until that time, we will 
call this kinase TPKIIGSK3/?. 
At present, it is impossible to determine which kinase 
actually works in Alzheimer’s disease brain. One of the 
candidates is cdc2 kinase [8,9], which resembles TPKII 
based on partial sequencing (unpublished data) and 
substrate specificity [4,23], however, TPKII works in 
normal brain [5]. On the other hand, we have no evi- 
dence that phosphorylation sites by TPKIIGSK3P are 
phosphorylated in normal brain. These sites are re- 
ported to be phosphorylated in PHF [6]. It is reasonable 
to think that TPKIIGSK3b, rather than TPKII (cdc2- 
like kinase), induces tau to the PHF-like state, however, 
the possibility remains that TPKII aids the phosphoryl- 
ation by TPKIIGSK3p with prior phosphorylation of 
tau in Alzheimer’s disease brain [5]. 
Another candidate for PHF-related kinase is MAP 
kinase [7,8]. Phosphorylation of MAP kinase activates 
its activity [17]. Since we purified TPKIIGSK3P as the 
kinase inducing PHF epitopes without the activation 
step of MAP kinase [1,4], we may not have detected the 
MAP kinase for the PHF-related kinase. Our results 
indicate that MAP kinase generates epitope changes to 
a lesser extent than does TPKI/GSK3p. Therefore, we 
have no evidence that MAP kinase precedes TPKI/ 
GSK3/3 in PHF formation. 
Mammalian TPKIIGSK3b is 77% homologous to the 
Drosophila gene, shaggy [30] or zesta-white 3 [31]. Mu- 
tations in this gene cause abnormal differentiation of 
the nervous system [32]. In transgenic flies, rat GSK3p, 
but not GSK3a, can be substituted for shaggy [33]. 
Actually, our histochemical analysis with anti-TPKI/ 
GSK3P antibodies suggested that the kinase plays an 
important role in the growth of axons during develop- 
ment of the brain (M. Takahashi et al., submitted else- 
where). Considering that degeneration of neurons is 
characteristic of Alzheimer’s disease, TPKIIGSK3b 
may be implicated also in the degeneration process. 
Further considering that GSK3/I is also identical to 
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c-jun kinase [27], and that a programmed cell death is 
mediated by c-jun [34], TPKIIGSK3B may regulate the 
cell death through gene expression. Breakdown of the 
regulation may lead to the pathological state. We found 
that TPKIIGSK3P was involved in amyloid ,6 protein- 
mediated neuronal cell death (A. Takashima et al., in 
press in Proc. Natl. Acad. Sci. USA). Tau phosphoryla- 
tion may be one step in the process. 
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